The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma

Kim, H. R.; Lim, Seung Taek; Kim, H. J.; Hwang, Soohyun; Park, J. K.; Shin, Eun Joo; Bae, Min Sun; Ou, Sai Hong Ignatius; Wang, J.; Jewell, Susan; Kang, Dae Ryong; Soo, Ross A.; Haack, Herbert; Kim, Joo Hang; Shim, Hyo Sup; Cho, Byoung Chul

doi:10.1093/annonc/mdt220

Cited by 112 publications

(91 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, our analysis is restricted to biomarkers tested in the routine setting in France. Thus, some important biomarkers commonly expressed in never smokers such as ROS1 (6% in never smokers) and RET rearrangements were not included in this study [24,25].…”

Section: Discussionmentioning

confidence: 99%

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

et al. 2015

View full text Add to dashboard Cite

Lung cancer in never-smokers (LCINS) (fewer than 100 cigarettes in lifetime) is considered as a distinct entity and harbours an original molecular profile. However, the epidemiological and molecular features of LCINS in Europe remain poorly understood.All consecutive newly diagnosed LCINS patients were included in this prospective observational study by 75 participating centres during a 14-month period. Each patient completed a detailed questionnaire about risk factor exposure. Biomarker and pathological analyses were also collected. We report the main descriptive overall results with a focus on sex differences.384 patients were included: 65 men and 319 women. 66% had been exposed to passive smoking (significantly higher among women). Definite exposure to main occupational carcinogens was significantly higher in men (35%versus8% in women). A targetable molecular alteration was found in 73% of patients (without any significant sex difference):EGFRin 51%,ALKin 8%,KRASin 6%,HER2in 3%,BRAFin 3%,PI3KCAin less than 1%, and multiple in 2%.We present the largest and most comprehensive LCINS analysis in a European population. Physicians should track occupational exposure in men (35%), and a somatic molecular alteration in both sexes (73%).

show abstract

Section: Discussionmentioning

confidence: 99%

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

et al. 2015

View full text Add to dashboard Cite

show abstract

“…114,115 It is estimated that ROS1 gene rearrangements occur in approximately 1% to 2% of patients with NSCLC; they occur more frequently in younger women with adenocarcinoma who are never smokers and in those who are negative for EGFR mutations, KRAS mutations, and ALK gene rearrangements (also known as triple-negative). [115][116][117] Crizotinib is very effective for patients with ROS1 rearrangements, with response rates of approximately 70%, including complete responses. 115 In 50 patients, crizotinib yielded a response rate of 66% (95% CI, 51%-79%); the median duration of response was 18 months.…”

Section: Ros1 Rearrangementsmentioning

confidence: 99%

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Ettinger¹,

Wood²,

Aisner³

et al. 2017

J Natl Compr Canc Netw

1,127

1,005

View full text Add to dashboard Cite

show abstract

“…38,39 As with ALK, ROS1 activation is driven by structural variants, with multiple different partners fusing to the C-terminal portion of ROS1 containing the cytoplasmic tyrosine kinase and driving downstream signaling through MAPK, JAK/STAT, and PI3K pathways. Common fusion partners include SLC34A2, CD74, and TPM3, among others.…”

Section: Expert Consensus Opinionmentioning

confidence: 99%

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

Aung

Donald

Ellison

et al. 2014

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

Context: In 2013, an evidence-based guideline was published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology to set standards for the molecular analysis of lung cancers to guide treatment decisions with targeted inhibitors. New evidence has prompted an evaluation of additional laboratory technologies, targetable genes, patient populations, and tumor types for testing. Objective: To systematically review and update the 2013 guideline to affirm its validity; to assess the evidence of new genetic discoveries, technologies, and therapies; and to issue an evidence-based update. Design: The College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology convened an expert panel to develop an evidence-based guideline to help define the key questions and literature search terms, review abstracts and full articles, and draft recommendations. Results: Eighteen new recommendations were drafted. The panel also updated 3 recommendations from the 2013 guideline. Conclusions: The 2013 guideline was largely reaffirmed with updated recommendations to allow testing of cytology samples, require improved assay sensitivity, and recommend against the use of

show abstract

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma

Cited by 112 publications

References 18 publications

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

Contact Info

Product

Resources

About